DexCom (DXCM) stock fell 6.0% on Friday, November 6, 2026, while the S&P 500 gained 0.3%. The company released no ...

DexCom, Inc. DXCM reported third-quarter 2026 adjusted earnings per share (EPS) of 73 cents, which beat the Zacks Consensus ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...

Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after the bell. Here’s what investors should know.

DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...

Hope they go out of business.why said that they decline the service I need I have type 2 diabetes not game ...

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

NOW PLAYING How Novo Nordisk, Wegovy And Ozempic Are Changing The Weight-Loss Game For Patients And Investors Instead, the inverse appears to be true, Dexcom said in a presentation Tuesday. Across all ...

DexCom DXCM recently announced the upcoming Canadian launch of its Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) ...

Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, ...

Net Income and Diluted Net Income Per Share: GAAP net income was $275.1 million, or $0.72 per diluted share, for the third ...